Immutep (NASDAQ:IMMP) Stock, Quote.Headers.trade-ideas

Immutep

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

Screenshot 2024-09-16 at 5.51.32 PM

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

BBLG

DRMA

IMMP

NCNA

NWTN

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September

movers image

Pre-Market Outlook

Movers

EZPW

GPRK

IART

IOVA

NAMS

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Biotech

Earnings Beats

Penny Stocks

Small Cap

Analyst Ratings

General

ANVS

ARQT

Immutep Limited (NASDAQ: IMMP) jumped 14.9% after it announced positive results from cohort B of the late-stage TACTI-003 (KEYNOTE-PNC-34) study.

Immutep Up as Combo Therapy Meets Carcinoma Study Goals

Immutep Limited - American Depositary Shares

Immutep Ltd

Immutep (IMMP) has released an update. Immutep Limited has initiated a Phase I clinical trial of IMP761, a pioneering LAG-3 agonist antibody aimed ...

Immutep Launches Groundbreaking Autoimmune Therapy Trial

In a report released on August 16, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on Immutep Ltd (PRRUF – Research Report), with a pr...

Immutep Ltd (PRRUF) Gets a Buy from Canaccord Genuity

Immutep (IMMP) has released an update. Immutep Limited, a biotechnology company, has reported no change in revenue, a 50.7% increase in other incom...

Immutep Reports Increased Loss Despite Higher Income

Immutep (IMMP) has released an update. S&P Dow Jones Indices has announced the September 2024 quarterly rebalance of the S&P/ASX Indices, with no c...

Immutep: Quarterly Rebalance of S&P/ASX Indices

Immutep (IMMP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Naureen Quibria from Capital...

Immutep's Innovative LAG-3 Focused Therapies Poised to Transform Advanced Cancer Treatments: A Buy Rating Overview

In a report released on September 9, Melissa Benson from Wilsons maintained a Buy rating on Immutep Ltd (PRRUF – Research Report), with a price tar...

Immutep Ltd (PRRUF) Receives a Buy from Wilsons

Analyst Naureen Quibria of Capital One Financial assigned a Buy rating on Immutep (IMMP – Research Report), retaining the price target of $8.00. Na...

Buy Rating for Immutep: Promising Developments in Oncology and Competitive Edge

Immutep (IMMP) has released an update. Immutep's latest clinical trial, TACTI-003, shows promising results for its novel immunotherapy, efti, when ...

Immutep's Efti Shows Promise in Cancer Therapy

Bell Potter analyst Thomas Wakim maintained a Buy rating on Immutep Ltd (PRRUF – Research Report) today and set a price target of A$0.70. The compa...

Immutep Ltd (PRRUF) Gets a Buy from Bell Potter

Naureen Quibria, an analyst from Capital One Financial, reiterated the Buy rating on Immutep (IMMP – Research Report). The associated price target ...

Buy Rating Affirmed for Immutep on Promising Efti Outlook Despite Mixed Study Interpretations

PRRUF

Press Releases

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Immutep Quarterly Activities Report Q4 FY24

Immutep to Participate in Upcoming Investor Conferences

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep's Efti in Soft Tissue Sarcoma

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Anika Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

Emergent BioSolutions

Editas Medicine

Fate Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

GRAIL

Heron Therapeutics

Inozyme Pharma

ITeos Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

Lyell Immunopharma

MeiraGTx Hldgs

Nkarta

Organogenesis Hldgs

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Voyager Therapeutics, Inc. - Common Stock

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Immutep

Immutep (IMMP) Forecast

Immutep (NASDAQ:IMMP) Stock, Quote.Headers.trade-ideas